Screener
Collegium Pharmaceutical, Inc. COLL Nucynta Products — 2030
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Years ended December 31, | Jornay PM | Belbuca | Nucynta Products | Symproic | Total |
|---|---|---|---|---|---|
| 2026 | $83,829 | $75,393 | $27,692 | $7,285 | $194,199 |
| 2027 | 83,829 | — | — | 7,285 | 91,114 |
| 2028 | 83,829 | — | — | 7,285 | 91,114 |
| 2029 | 83,829 | — | — | 7,285 | 91,114 |
| 2030 | 83,829 | — | — | 7,285 | 91,114 |
| Thereafter | 104,783 | — | — | 6,072 | 110,855 |
| Remaining amortization expense | $523,928 | $75,393 | $27,692 | $42,497 | $669,510 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s nucynta products — 2030?
- Collegium Pharmaceutical, Inc. (COLL) reported nucynta products — 2030 of $0 in Q4 2025.
- What does nucynta products — 2030 mean?
- This metric represents the total amortization expense associated with the Nucynta product line, reflecting the systematic allocation of the cost of intangible assets over their estimated useful lives. It serves as a key indicator of the non-cash accounting charges related to the acquisition or development of these specific pharmaceutical assets. Monitoring this expense helps investors understand the impact of asset valuation on the segment's reported profitability and the remaining carrying value of the product portfolio.
Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta products — 2030.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude